Citi Pharma Limited (PSX: CPHL) recorded a 22.14% year-on-year increase in consolidated net profit for the first quarter ended September 30, 2026 (1QFY27), reaching PKR 248.79 million compared to PKR 203.69 million in the same period last year.
Basic and diluted earnings per share (EPS) grew 22.47% to PKR 1.09 from PKR 0.89. Profitability was supported by a 29.92% surge in gross profit alongside a 16.93% reduction in finance costs, though a sharp rise in marketing expenses (+122.58%) and higher tax charges (+46.47%) partially trimmed the bottom-line expansion.
| Financial Metric | 1QFY27 (PKR) | 1QFY26 (PKR) | YoY Change (%) |
|---|---|---|---|
| Net Sales | 3,514,442,888 | 3,370,247,671 | 4.28% |
| Gross Profit | 674,262,488 | 518,973,622 | 29.92% |
| Operating Profit | 511,162,226 | 420,355,037 | 21.60% |
| Finance Costs | (100,672,701) | (121,191,504) | -16.93% |
| Profit After Tax | 248,792,484 | 203,690,873 | 22.14% |
| EPS (PKR) | 1.09 | 0.89 | 22.47% |
Investor Takeaway: Citi Pharma delivered strong bottom-line growth driven by gross margin expansion and reduced financial charges, despite notable selling and tax expense pressures during the quarter.
Read the full story on the original publisher’s website.
Open original article